Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BWV-401
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Texas Health Science Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, BWV will fund the NHP study to further evaluate the efficacy of BWV-401, a live attenuated, orally delivered Chlamydia vaccine, and provide additional support for development towards human clinical trials.
Product Name : BWV-401
Product Type : Vaccine
Upfront Cash : Undisclosed
December 04, 2023
Lead Product(s) : BWV-401
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Texas Health Science Center
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Virus-like Particle Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : Virus-like Particle Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finasteride,Tadalafil
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : IQVIA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Blue Water Biotech and IQVIA will market Blue Water’s commercial portfolio including, Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for benign prostatic hyperplasia and Zontivity (vorapaxar).
Product Name : Entadfi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 21, 2023
Lead Product(s) : Finasteride,Tadalafil
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : IQVIA
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Monkeypox Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : AbVacc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Blue Water Vaccines and AbVacc will collaborate for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease. Both candidate vaccines will utilize BWV’s norovirus shell and protrusion VLP platform.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 02, 2023
Lead Product(s) : Monkeypox Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : AbVacc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Chlamydia Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Texas Health San Antonio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Blue Water Vaccines Announces Agreement for Chlamydia Development
Details : Chlamydia vaccines have historically been challenging to produce, but the novel approach has demonstrated strong results in mouse models, which will translate into a human vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
November 21, 2022
Lead Product(s) : Chlamydia Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Texas Health San Antonio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BWV-201
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New data, based on experiments at St. Jude Children’s Research Hospital, suggests that BWV-201 may also provide protection against pneumococcal pneumonia by limiting the ability of Streptococcus pneumoniae to infect the lungs.
Product Name : BWV-201
Product Type : Vaccine
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : BWV-201
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BWV-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Private Placement
Details : The Company intends to use the net proceeds from the private placement for the research and development of its pipeline as well as for working capital and other general corporate purposes.
Product Name : BWV-101
Product Type : Vaccine
Upfront Cash : Undisclosed
November 08, 2022
Lead Product(s) : BWV-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Private Placement
Lead Product(s) : BWV-201
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : St. Jude Children’s Research Hospital
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Blue Water Vaccines originally licensed patent rights from St. Jude in order to develop a live attenuated bacterial vaccine (candidate BWV-201) for acute otitis media (AOM) caused by Streptococcus pneumoniae colonization in the middle ear cavity.
Product Name : BWV-201
Product Type : Vaccine
Upfront Cash : Undisclosed
November 05, 2022
Lead Product(s) : BWV-201
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : St. Jude Children’s Research Hospital
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BWV-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022
Details : The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus, S&P nanoparticle versatile virus-like particle vaccine platform from CCHMC to develop vaccines for multip...
Product Name : BWV-101
Product Type : Vaccine
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : BWV-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Cincinnati Children’s Hospital Medical Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the SRA, BWV will further fund research into this platform’s versatility across other diseases, including influenza and Alzheimer’s disease. Tan has a financial interest in the virus-like particle (VLP) vaccine platform technology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Cincinnati Children’s Hospital Medical Center
Deal Size : Undisclosed
Deal Type : Agreement